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Systemic lupus erythematosus
without clinical renal
abnormalities
SIR, We read with interest the study of O'Dell et all
showing a high incidence of mesangial changes in renal
biopsies from patients with systemic lupus erythematosus
(SLE) without clinical renal abnormalities. They found no
cases of focal or diffuse proliferative glomerulonephritis.
These results are different from those previously reported
by other authors2 3 and question the relevance of renal
biopsy in these patients.
Recently we have performed renal biopsy in 13 patients
with SLE (fulfilling the American Rheumatism Associ-
ation revised criteria4) who had no clinical signs of renal
involvement (no urinary sediment abnormalities, absence
of proteinuria, and serum creatinine below 1-3 mg/dl (115
tLmol/1)). All renal biopsy specimens were examined by
two pathologists and categorised according to the modified
classification proposed by the World Health
Organisation.
Five cases (38%) showed no histological or immuno-
fluorescence changes (type I), six (46%) patients had a
mesangial nephropathy (three type Ila and three type Ilb),
and two (15%) had a focal proliferative glomerulonephritis
(type III). None of the patients had previous evidence of
neurological abnormalities. Patients with normal renal
biopsies (type I) only had arthritis, skin lesions, and
Raynaud's phenomenon. In contrast, six patients with
histological renal involvement had serositis or haemolytic
anaemia. All cases with silent nephropathy were treated
with steroids and showed a benign clinical course with
stable renal function and absence of urinary abnormalities
during follow up (one to 76 months, mean 27 months).
On the basis of these results we agree with O'Dell et al'
that, in the absence of clinical renal abnormalities,
significant renal involvement is uncommon in SLE.
However, as reported by Mahajan et a12 and Lehey et a13
and confirmed in the present study, a few patients may
have severe renal lesions requiring steroid therapy. Thus
until more information becomes available we believe that a
renal biopsy should be performed in those SLE patients
presenting with clinical manifestations other than arthritis
or cutaneous lesions since this policy may allow detection
of silent nephritis lesions.
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SIR, We appreciated the letter of Font et al and the
opportunity to respond to it. The findings of Font et al that
none of the 13 lupus patients without clinical evidence of
renal disease had diffuse proliferative glomerulonephritis
are very similar to our findings but very different from the
findings of Mahajan et al. l We were surprised that five of
the 13 lupus patients in their study (Font et a!) had
completely normal renal biopsies. All of our patients,
despite the absence of clinical renal abnormalities, had
mesangial abnormalities as shown either by light micro-
scopy or by immunofluorescence studies. Our findings are
similar to those of most other studies published in the
literature, which show that most patients, despite the
absence of clinical renal disease, have abnormalities on
renal biopsies.'
We do not agree with the recommendation of Font et al
that because they found focal proliferative glomeru-
lonephritis in two of their patients they would advocate
renal biopsies in lupus patients in the absence of clinical
renal abnormalities. As stated in our paper there is no
evidence in the literature to suggest that early treatment of
histopathological abnormalities found on renal biopsy in
the absence of clinical findings will in any way influence
prognosis. In fact, all studies in lupus nephritis that have
looked at the question have concluded that clinical
parameters are a much stronger indication of prognosis
than histological classification.
 group.bmj.com on July 20, 2011 - Published by ard.bmj.comDownloaded from 
Correspondence 261
In summary, we agree with the findings of Font et al that
significant renal pathology in lupus patients without
clinical renal abnormalities is rare, but we do not advocate
renal biopsy in this group of patients.
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Ankylosing spondylitis,
HLA-B27, and klebsiella
SIR, With particular reference to our studies1 2 and those of
Ebringer and his associates,3 4 the article by Singh et al (p.
190, this issue), attempts to address the controversial issue
of cross reactivity between certain strains of klebsiella
and the lymphocytes of HLA-B27 positive patients
with ankylosing spondylitis (B27+AS+). Controversy is a
healthy byproduct of scientific interest, and it is essential
that our findings and those of other workers in the field be
subjected to the closest scrutiny and evaluation. Those
entering this debate, however, should do so with a sense of
responsibility; presentation of data which are based on
questionable or inadequately controlled techniques must
be considered scientifically misleading. I refer specifically
to the 'tCr release technique used by Singh et al that
attempts to reproduce the specific cytotoxicity of anti-
klebsiella sera for B27'AS' cells. There are several
important differences between their technique and ours,
and their departure from our published methods passes
without comment or justification. Firstly, the 51Cr labelled
cells are incubated simultaneously with antiserum and
diluted complement for one hour at 370C. The more
conventional method and the one favoured by our group is
to incubate the radiolabelled cells with antiserum for 30
min at room temperature (20-240C) before adding neat
complement for a further 60 min at the same temperature.
Secondly, Singh et al complete their assay by adding to
each tube 1-5 ml of cold 0-9% NaCl. The significance of
this cold saline step is not entirely clear. We have recently
tested five B27+AS+ cells (which were positive with our
"Cr release technique) according to the Singh method and
we were unable to demonstrate cross reactivity between
klebsiella K43 BTS1 and other enteric bacteria and the
patients' lymphocytes. Furthermore, the failure of the
Singh method in our hands is due largely to the simul-
taneous, rather than sequential, addition of antiserum and
complement. Singh et al justify their choice of this
unconventional cytotoxicity technique by pointing out that
. . 'high levels of cytotoxicity were obtained against the
lymphocytes in control tests with antilymphocytic serum'.
However, most antilymphocytic sera are active in the
absence of complement and since details on the production
and source of this reagent are not given in the paper one
assumes that the success of their assay technique rests
largely on the activity of an alloantiserum, anti-HLA-B27.
We have been concerned by the non-confirmatory
reports of this work and in an attempt to identify some of
the factors which might contribute to the failure of others
to confirm our findings we have recently completed a
double blind trial involving B27+AS+ cells from a New
Zealand population.5 This successful study, together with
two previous confirmatory reports (in preparation),6 sug-
gests that the phenomenon of 'cross reactivity' between
enteric bacteria and B27'AS' cells is not simply an
Antipodean curiosity.7 Although many aspects of this
controversy remain to be resolved, it is worth noting that
of the non-confirmatory reports only Beaulieu et at8 have
adhered to our published methods, while other workers
found it necessary to modify one or more parameters of the
51Cr release assay.
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